IELSG47 Study

IELSG47 MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
Participants required: 175 (130 patients with EMZL + 30 SMZL and 15 NMZL)
Investigator responsible(s): C.Thieblemont, A. Conconi
Objective(s): Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset.

Home | Go to Studies